A clinician view and experience of proteomic studies in the light of lung cancer in japanese healthcare

Journal of Proteome Research

Volumn 10, Issue 1, 2011, Pages 51-57

  Kato, Harubumi ^a,b,c   Nishimura, Toshihide ^c,d,e   Hirano, Takashi ^f   Nomura, Masaharu ^c   Tojo, Hiromasa ^g   Fujii, Kiyonaga ^h   Kawamura, Takeshi ⁱ   Mikami, Sayaka ^e   Kihara, Makoto ^d   Bando, Yasuhiko ^e   Tsuboi, Masahiro ^c   Ikeda, Norihiko ^c   Marko Varga, Gyorgy ^c,j  

^a Niizashiki Chuo General Hospital   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Medical ProteoScope Co Ltd   (Japan)

^e Biosys Technologies Inc   (United States)

^f Toda Central General Hospital   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HOKKAIDO UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j LUND UNIVERSITY   (Sweden)

more..

Author keywords

Diagnosis and treatment; Healthcare; Lung cancer; Proteomic study

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; GEFITINIB; TEGAFUR; URACIL;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; HEALTH CARE; HUMAN; JAPANESE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ADULT; AGED; AREA UNDER CURVE; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 79951533736     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100859b     Document Type: Review

References (36)

1. The Insurance Bureau, Ministry of Health, Labour and Welfare, Upon The Revised Medical Rewards 2010, March 5, 2010: http://www. mhlw.go.jp/bunya/ iryouhoken/iryouhoken12/setumei.html.
2. Davis, J. C.; Furstenthal, L.; Desai, A. A.; Norris, T.; Sutaria, S.; Fleming, E.; Ma, P. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discovery 2009, 8, 279-286.
3. Davis, J. C.; Furstenthal, L.; Desai, A. A.; Norris, T.; Sutaria, S.; Fleming, E.; Ma, P. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discovery 2009, 8, 279-286, supplement information.
4. McWilliam, A. et al. Health care savings from personalizing medicine using genetic testing: the case of warfarin. Brookings Joint Center working paper, 2006.
5. Horberger, J. Economic analysis of targeting chemotherapy using a 21-gene RTPCR Assay in lymph-node-negative, estrogen-receptor- positive, early-stage breast cancer. Am. J. Managed Care 2005, 11 (5), 313-324.
6. OECD Health Data 2009, Oct. 21, 2010: http://www.ecosante.org/oecd.htm.
7. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S. A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6 (12), 2212-29.
8. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S. A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2008, 7 (10), 1952-62.
9. Addona, T. A.; Abbatiello, S. E.; Schilling, B.; Skates, S. J.; Mani, D. R.; Bunk, D. M.; Spiegelman, C. H.; Zimmerman, L. J.; Ham, A.-J. L.; Keshishian, H.; Hall, S. C.; Allen, S.; Blackman, R. K.; Borchers, C. H.; Buck, C.; Cardasis, H. L.; Cusack, M. P.; Dodder, N. G.; Gibson, B. W.; Held, J. M.; Hiltke, T.; Jackson, A.; Johansen, E. B.; Kinsinger, C. R.; Li, J.; Mesri, M.; Neubert, T. A.; Niles, R. K.; Pulsipher, T. C.; Ransohoff, D.; Rodriguez, H.; Rudnick, P. A.; Smith, D.; Tabb, D. L.; Tegeler, T. J.; Variyath, A. M.; Vega-Montoto, L. J.; Wahlander, A.; Waldemarson, S.; Wang, M.; Whiteaker, J. R.; Zhao, L.; Anderson, N. L.; Fisher, S. J.; Liebler, D. C.; Paulovich, A. G.; Regnier, F. E.; Tempst, P.; Carr, S. A. Multi-site assessment of the precision and reproducibility of multiple reaction monitoringbased measurements of proteins in plasma. Nat. Biotechnol. 2009, 27 (7), 633-41.
10. Hirano, T.; Kato, H. Present status of clinical proteomic analysis for the early detection and determination of therapeutic strategy in lung cancer. Ann. Thorac. Cardiovasc. Surg. 2006, 12 (1), 4-9.
11. Moran, C. A.; Suster, S.; Coppola, D.; Wick, M. R. Neuroendocrine Carcinomas of the Lung A Critical Analysis. Am. J. Clin. Pathol. 2009, 131 (2), 206-21.
12. Brambilla, E. WHO 1999 classification of lung cancers: a guided tour. Ann. Pathol. 1999, 19 (5 Suppl), S47-9.
13. Patent PCT; WO2007144606A2.
14. US Patent Application No. 61/313154 (2010. -03-12).
15. US Patent Application No. 61/298,005.
16. Prieto, D. A.; Hood, B. L.; Darfler, M. M.; Guiel, T. G.; Lucas, D. A.; Conrads, T. P.; Veenstra, T. D.; Krizman, D. B. Liquid Tissue: proteomic profiling of formalin-fixed tissues. BioTechniques 2005, 38, S32-5.
17. Hood, B. L.; Conrads, T. P.; Veenstra, T. D. Unravelling the proteome of formalin-fixed paraffin-embedded tissue. Brief Funct. Genomics 2006, 5 (2), 169-75. (Pubitemid 46403009)
18. Hood, B. L.; Conrads, T. P.; Veenstra, T. D. Mass spectrometricanalysis of formalin-fixed paraffin-embedded tissue: Unlocking the proteome within. Proteomics 2006, 6 (14), 4106-14.
19. Nishimura, T.; Nomura, M.; Fukuda, T.; Fujii, K.; Kawamura, T.; Hamasaki, H.; Hike, H.; Bando, Y.; Ikeda, N.; Kato, H. MRM MSBased Assays To Identify Biomarkers for Lung Carcinoma of Largecell Neuroendocrine (LCNEC) 2009/6/14, 3rd EuPA Congress, Sweden;ISBN 978-963-86156-4-0; OOK-PRESS Kft, H-8200 Veszprem: Hungary, 2006.
20. Vegvari, A.; Marko-Varga, G. Clinical Protein Science and Bioanalytical Mass Spectrometry with an Emphasis on Lung Cancer. Chem. Rev. 2010, 110 (5), 3278-98.
21. Fehniger, T. E.; Marko-Varga, G. Proteomics and disease revisited: the challenge of providing proteomic tools into clinical practice. J. Proteome Res. 2010, 9 (3), 1191-2.
22. Lowe, S. W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266 (5186), 807-10. (Pubitemid 24359290)
23. Cho, J. Y.; Kim, J. H.; Lee, Y. H.; Chung, K. Y.; Kim, S. K.; Gong, S. J.; You, N. C.; Chung, H. C.; Roh, J. K.; Kim, B. S. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 1997, 79 (3), 462-7. (Pubitemid 27051769)
24. Britten, R. A.; Dan, L. D.; Tessier, A.; Hutchison, M. J.; David, M. D. ERCC1 Expression as A Molecular Marker of Cisplatin Resistance in Human Cervical Tumor Cells. Int. J. Cancer 2000, 89 (5), 453-457.
25. Hirano, T.; Kato, H.; Maeda, M.; Gong, Y.; Shou, Y.; Nakamura, M.; Maeda, J.; Yashima, K.; Kato, Y.; Akimoto, S.; Ohira, T.; Tsuboi, M.; Ikeda, N. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int. J. Cancer 2005, 117 (3), 460-8. (Pubitemid 41429570)
26. Marko-Varga, G.; Ogiwara, A.; Nishimura, T.; Kawamura, T.; Fujii, K.; Kawakami, T.; Kyono, Y.; Tu, H.; Anyoji, H.; Kanazawa, M.; Akimoto, S.; Hirano, T.; Tsuboi, M.; Nishio, K.; Hada, S.; Jiang, H.; Fukuoka, M.; Nakata, K.; Nishiwaki, Y.; Kunito, H.; Peers, I. S.; Harbron, C. G.; South, M. C.; Higenbottam, T.; Nyberg, F.; Kudoh, S.; Kato, H. Personalized Medicine and Proteomics Lessons from Non-Small Cell Lung Cancer. J. Proteome Res. 2007, 6 (8), 2925-35. (Pubitemid 47315558)
27. Ogiwara, A.; Kawakami, T.; Nagasaka, K.; Tanaka. N.; Wada, K.; Otsuji, M.; Komatsu, Y.; Nishimura, T.; Harbron, C. G.; Nyberg, F.; Marko-Varga, G. Keys to success for large-scale proteomic analysis conducted with a clinical study. 3rd EuPA Congress, Sweden; ISBN 978-963-86156-4-0; OOK-PRESS Kft, H-8200 Veszprem: Hungary, 2006; pp 252-4.
28. Kato, H.; Ichinose, Y.; Ohta, M.; Hata, E.; Tsubota, N.; Tada, H.; Watanabe, Y.; Wada, H.; Tsuboi, M.; Hamajima, N.; Ohta, M. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004, 350 (17), 1713-21. (Pubitemid 38501140)
29. The Japan Lung Cancer Society. EMB by lung cancer diagnosis and treatment guideline 2005, Dec. 1, 2006; http://www.haigan.gr.jp/modules/guideline/.
30. Maeda, J.; Hirano, T.; Ogiwara, A.; Akimoto, S.; Kawakami, T.; Fukui, Y.; Oka, T.; Gong, Y.; Guo, R.; Inada, H.; Nawa, K.; Kojika, M.; Suga, Y.; Ohira, T.; Mukai, K.; Kato, H. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br. J. Cancer 2008, 98 (3), 596-603. (Pubitemid 351214526)
31. Staging Manual in Thoracic Oncology; International Association for the Study of Lung Cancer, Peter Goldstraw, Ed.; Editorial Rx Press: 2009.
32. Kawamura, T.; Nomura, M.; Tojo, H.; Fujii, K.; Hamasaki, H.; Mikami, S.; Bando, Y.; Kato, H.; Nishimura, T. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stagerelated protein candidates upon non-metastatic lung adenocarcinoma. J. Proteomics 2010, 73 (6), 1089-99.
33. Nishimura, T.; Nomura, M.; Tojo, H.; Hamasaki, H.; Fukuda, T.; Fujii, K.; Mikami, S.; Bando, Y.; Kato, H. Proteomic analysis of lasermicrodissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J. Proteomics 2010, 73 (6), 1100-10.
34. Maniwa, J. Oral presentation at 8th Japan Human Proteome Organization Conference (JHUPO)/6th Annual Meeting of Japan Society for Clinical Proteomics (JSCP) Joint Conference, July 26-27, 2010 at Tokyo Bay Hotel Tokyu, Chiba, Japan http://www.tokyuhotelsjapan.com/en/TH/TH-TKBAY/index.html.
35. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350 (21), 2129-39. (Pubitemid 38637993)
36. Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B. H.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H. Y.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or Carboplatin- Paclitaxel in Pulmonary Adenocarcinoma. N. Engl. J. Med. 2009, 361 (10), 947-57.